PSOC

NANTES, France, May 22, 2026 OSE Immunotherapeutics announced positive topline results from the Phase 2 TEDOVA trial evaluating Tedopi®...

North Chicago, Illinois | April 12, 2026 AbbVie has announced late-breaking Phase 2 clinical trial results demonstrating strong efficacy...